In terms of clinical outcome, patients with higher DBN1 tumour levels in the METABRIC cohort had an unfavourable outcome compared with those patients with low DBN1 expression (p < 0.05; Figure 3A–C). This evidence concerns the gene DBN1 and neoplasm.